Rifampicin News and Research

RSS

Report: Global increase in drug-resistant TB threatens to ruin efforts to eradicate the disease

The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) threatens to derail decades of progress in controlling the disease, according to a new report in The Lancet Respiratory Medicine published on World TB day (24th March).

25 Mar 2017

New study proves that 'super-boosting' approach may help treat children co-infected with TB and HIV

The non-profit research and development organization Drugs for Neglected Diseases initiative has released results of a study in South Africa that will make it easier for healthcare workers to treat children living with HIV who are co-infected with tuberculosis.

14 Feb 2017

New ‘release and kill’ strategy may shorten treatment periods for patients with tuberculosis

Mycobacterium tuberculosis has been called "the perfect pathogen." These bacteria hijack human macrophages, persist inside the cells to evade immune destruction, and then prevent the macrophage from undergoing programmed cell death.

8 Feb 2017

Detailed analysis of bacterial proteins offers path for new drugs to curb tuberculosis

With the first detailed analysis of a cellular component from a close relative of the pathogen that causes tuberculosis, Rockefeller scientists are suggesting strategies for new drugs to curb this growing health problem.

6 Feb 2017

Scientists identify key 'survival gene' that reduces mutation rates in mycobacteria

Scientists have discovered a key 'survival gene' that prevents strains of tuberculosis (TB) from mutating into drug-resistant 'superbugs'.

28 Jan 2017

International travellers may spread antimicrobial-resistant bacteria in their home countries, study reveals

Airports are international travel hubs visited by large numbers of people. London Heathrow, for example, has an average of 205,400 travellers every day and saw 75 million people arriving and departing from all over the world in 2015.

3 Nov 2016

Virginia Tech scientists solve structure of enzyme that deactivates important antibiotic

A popular antibiotic called rifampicin, used to treat tuberculosis, leprosy, and Legionnaire's disease, is becoming less effective as the bacteria that cause the diseases develop more resistance.

7 Oct 2016

MIP vaccine could reduce new leprosy cases in India by 60%

The Indian government has announced that it is stepping up its efforts to eradicate leprosy by testing a vaccine that if successful could cut the number of new reported cases by 60 per cent in three years in the targeted districts.

15 Sep 2016

Study provides insight into why individual mycobacteria respond differently to antibiotics

Tuberculosis is one of the most common infectious diseases in the world, infecting almost 10 million people each year. Treating the disease can be challenging and requires a combination of multiple antibiotics delivered over several months.

4 Jul 2016

New ultra-fast molecular method can help detect mycobacterial pathogens in the lungs

What used to take several weeks is now possible in two days: Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.

24 Jun 2016

Cochrane review explores FDCs versus single-drug formulations for treatment of pulmonary TB

A research team from Spain has prepared a Cochrane systematic review that explores the efficacy, safety, and adherence to fixed-dose combinations (FDCs) of drugs versus single-drug formulations to treat people who are newly diagnosed with tuberculosis (TB).

23 May 2016

Novel rapid diagnostic test and shorter treatment with better outcomes may benefit MDR-TB patients

New WHO recommendations aim to speed up detection and improve treatment outcomes for multidrug resistant tuberculosis (MDR-TB) through use of a novel rapid diagnostic test and a shorter, cheaper treatment regimen.

12 May 2016

Health officials to attend International Summit on Tuberculosis and Diabetes in Bali, Indonesia

Health officials from the governments of Indonesia and India will join advocates, civil society groups, researchers and businesses from Asia, Europe, Latin America and North America in Bali, Indonesia on 2-3 November at the world’s first International Summit on Tuberculosis (TB) and Diabetes in an effort to avert a global health crisis.

7 Oct 2015

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy.

26 Aug 2015

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label.

11 Aug 2015

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.

2 Jun 2015

Boehringer announces LUX-Lung 8 data that compares efficacy of afatinib, erlotinib in patients with advanced SCC

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.

1 Jun 2015

New TB-Profiler tool to find appropriate drugs for TB patients may improve likelihood of cure

Finding out what drugs can be used to treat a patient with tuberculosis (TB) can be sped up by days or weeks, thanks to a new free online tool. The new TB-Profiler tool, developed by a team of scientists led by Dr Taane Clark at the London School of Hygiene & Tropical Medicine, analyses and interprets genome sequence data to predict resistance to 11 drugs used for the treatment of TB.

29 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF).

15 Oct 2014